CPHI [CHINA PHARMAS,] CORRESP: April 22, 2010 Division ofrporation Finance 100 F

[April 22, 2010 Division ofrporation Finance 100 F Street N.E. Attn: Bryan Pitko Re:China Pharmas, Preliminary Information Statement on Form PRE 14C Filed April 1, 2010 File No.001-34471 Dear Mr. Bryan Pitko,mpanymment Letter Form PRE 14C On behalf of China Pharmas, a Delawarerporation (the]

By | 2016-02-07T23:36:40+00:00 April 22nd, 2010|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] PRER14C: SCHEDULE 14C INFORMATION Amendment No. 1 I Check

[SCHEDULE 14C INFORMATION Amendment No. 1 I Check the appropriate box: [X] Preliminary Information Statement [] [] Definitive Information Statement CHINA PHARMAS, Payment of Filing Fee (Check the appropriate box): [X] No fee required. [] Feemputed on table below per Exchange Act Rules 14c-5(g) and 0-11. 1) Title of each class of securities to which]

By | 2016-02-07T23:38:30+00:00 April 22nd, 2010|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-A12B: (Original Filing)

[FORM 8-A FOR REGISTRATION OF CERTAIN CLASES OF SECURITIES BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State of incorporation or organization) ( I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province, The People’s Republic of China 712046 (Zip Code) Title of each class to be registered: Name of each exchange on which each class is to be registered: Common]

By | 2016-03-03T14:37:47+00:00 April 21st, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-A12B: FORM 8-A FOR REGISTRATION OF CERTAIN CLASES OF

[FORM 8-A FOR REGISTRATION OF CERTAIN CLASES OF SECURITIES BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State of incorporation or organization) ( I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province, The People’s Republic of China 712046 (Zip Code) Title of each class to be registered: Name of each exchange on which each class is to be registered: Common]

By | 2016-03-03T14:38:48+00:00 April 21st, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-A12B: (Original Filing)

[FORM 8-A FOR REGISTRATION OF CERTAIN CLASES OF SECURITIES BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State oforporationororganization) (I.R.S.EmployerIdentificationNo.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province, The Peoples Republic of China 712046 (Zipde) Title of each class to be registered: Name of each exchange on which each class is to be registered:]

By | 2016-02-07T17:31:59+00:00 April 21st, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-A12B: FORM 8-A FOR REGISTRATION OF CERTAIN CLASES OF

[FORM 8-A FOR REGISTRATION OF CERTAIN CLASES OF SECURITIES BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State oforporationororganization) (I.R.S.EmployerIdentificationNo.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province, The Peoples Republic of China 712046 (Zipde) Title of each class to be registered: Name of each exchange on which each class is to be registered:]

By | 2016-02-07T17:32:54+00:00 April 21st, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT (this “ WHEREAS, the Company desires to employ Executive as its Chief Financial Officer on the terms and conditions as set forth hereinafter, and Executive desires to be so employed; NOW, THEREFORE, IN CONSIDERATION of the foregoing facts, the mutual covenants and agreements contained herein and other good and valuable consideration, the] [SERVICES AGREEMENT 16 This SERVICES AGREEMENT (this “Agreement”), dated as of April RECITALS: B. The Parties have previously entered into an agreement setting forth the terms for the services of the Consultant as the Representative through March 31, 2010. C. At the request of the Company, the Consultant has continued to provide services to the Company as the Representative since] [SKYSTAR BIO-PHARMACEUTICAL COMPANY RESTRICTED STOCK AWARD AGREEMENT This Restricted Stock Award Agreement Agreement Company Grantee In consideration of the covenants herein set forth, the parties hereto agree as follows: Stock Award Information. 1. (a) Date of Award: April 16, 2010 (b) Grantee: R. Scott Cramer (c) Number of Shares: 10,000 (d) Original Value: $ (e) Amount Paid for Shares by] [SKYSTAR APPOINTS NEW CHIEF FINANCIAL OFFICER Michael H. Lan to Become Permanent CFO XI'AN, CHINA – April 19, 2010 - Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) ("Skystar" or the "Company"), Mr. Lan has advanced knowledge of U.S. GAAP and financial reporting requirements and has held internal financial control and audit positions with Silgan Containers Corporation and Gilead Sciences. Immediately prior to joining]

By | 2016-03-01T06:20:29+00:00 April 19th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)

[EMPLOYMENTREEMENTreement Executivempany This EMPLOYMENTREEMENT (this WHEREAS, thempany desires to employ Executive its Chief Financial Officer on the terms andnditions set forth hereinafter, and Executive desires to be so employed; NOW, THEREFORE, INNSIDERATION of the foregoing facts, the mutualvenants andreementsntained herein and other good and valuablensideration, the parties herebyree follows:] [SERVICESREEMENT 16 This SERVICESREEMENT (thisreement),ted of April RECITALS: B.The Parties have previously entered into anreement setting forth the terms for the services of thensultant the Representative through March 31, 2010. C.At the request of thempany, thensultant hasntinued to provide services to thempany the Representative since April 1, 2010, and the Parties now desire to memorialize] [SKYSTAR BIO-PHARMACEUTICALMPANY RESTRICTED STOCK AWARDREEMENT This Restricted Stock Awardreementreementmpany Grantee Innsideration of thevenants herein set forth, the parties heretoree follows: Stock Award Information. 1. (a)te of Award: April 16, 2010 (b) Grantee: R.ott Cramer (c) Number of Shares: 10,000 (d)] [SKYSTAR APPOINTS NEW CHIEF FINANCIAL OFFICER Michael H. Lan to Become Permanent CFO XI'AN, CHINA April 19, 2010 -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), Mr. Lan hasvanced knowledge of U.S. GAAP and financial reporting requirements and has held internal financialntrol and audit positions with Silganntainersrporation and Gileadiences.Immediately prior to joiningystar, Mr. Lan was founder]

By | 2016-02-05T04:25:59+00:00 April 19th, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 20-F: (Original Filing)

[FORM 20-F (Mark One) o OR x For the fiscal year ended December 31, 2009 OR o For the transition period from to OR o Date of event requiring this shell company report . . . . . . . . . . . . . . . . . . . SINOVAC BIOTECH LTD. N/A Antigua, West Indies (Jurisdiction] [Asset Acquisition Agreement In Relation to Guangda Pharmaceutical Party A: Beijing Xingchang High-tech Development Corporation Legal Representative: Hailing Wang Address: No. 9 Chaoqian Road, Changping District Beijing Party B: Sinovac Biotech Co., Ltd. Legal Representative: Aihua Pan Address: No. 39 Shangdi West Road, Haidian District Beijing Whereas: 1. Party A is a development enterprise located in the Changping Section of] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Beijing Sinovac Biological Technology Co., Ltd., a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company 1 EX-8.1 3 a10-7773_2ex8d1.htm EX-8.1] [Certification by the Chief Executive Officer I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Financial Officer I, Jinling Qin , certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER In connection with the Annual Report of Sinovac Biotech Ltd. Weidong Yin 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 16, 2010 1 EX-13.1 6 a10-7773_2ex13d1.htm EX-13.1] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER In connection with the Annual Report of Sinovac Biotech Ltd. Jinling Qin 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 16, 2010 1 EX-13.2 7 a10-7773_2ex13d2.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-161827) pertaining to the 2003 Stock Option Plan of Sinovac Biotech Ltd., of our reports dated April 16, 2010, with respect to the consolidated financial statements of Sinovac Biotech Ltd., and the effectiveness of internal control over financial reporting]

By | 2016-03-24T03:10:37+00:00 April 16th, 2010|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments

SVA [SINOVAC BIOTECH] 20-F: FORM 20-F (Mark One) o OR x For

[FORM 20-F (Mark One) o OR x For the fiscal year ended December 31, 2009 OR o For the transition period from to OR o Date of event requiring this shell company report . . . . . . . . . . . . . . . . . . . SINOVAC BIOTECH LTD. N/A Antigua, West Indies (Jurisdiction] [Asset Acquisition Agreement In Relation to Guangda Pharmaceutical Party A: Beijing Xingchang High-tech Development Corporation Legal Representative: Hailing Wang Address: No. 9 Chaoqian Road, Changping District Beijing Party B: Sinovac Biotech Co., Ltd. Legal Representative: Aihua Pan Address: No. 39 Shangdi West Road, Haidian District Beijing Whereas: 1. Party A is a development enterprise located in the Changping Section of] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Beijing Sinovac Biological Technology Co., Ltd., a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company 1 EX-8.1 3 a10-7773_2ex8d1.htm EX-8.1] [Certification by the Chief Executive Officer I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Financial Officer I, Jinling Qin , certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER In connection with the Annual Report of Sinovac Biotech Ltd. Weidong Yin 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 16, 2010 1 EX-13.1 6 a10-7773_2ex13d1.htm EX-13.1] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER In connection with the Annual Report of Sinovac Biotech Ltd. Jinling Qin 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 16, 2010 1 EX-13.2 7 a10-7773_2ex13d2.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-161827) pertaining to the 2003 Stock Option Plan of Sinovac Biotech Ltd., of our reports dated April 16, 2010, with respect to the consolidated financial statements of Sinovac Biotech Ltd., and the effectiveness of internal control over financial reporting]

By | 2016-03-24T03:11:31+00:00 April 16th, 2010|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar